Form 4: Stoke Therapeutics Executive Sells Shares

Sentiment:

Insider Transaction (Form 4)


Jonathan Allan, GENERAL COUNSEL & CORP SEC of Stoke Therapeutics, Inc., sold 2,861 shares of common stock on August 14, 2026.

Summary

  • Option exercise/conversion: acquired 6,000 Common Stock on August 14, 2026; holds 24,086 after (Direct).
  • Open-market sale: disposed of 2,716 Common Stock at $32.01 ($86,932) on August 18, 2026; holds 21,370 after (Direct).
  • Open-market sale: disposed of 145 Common Stock at $32.47 ($4,708) on August 18, 2026; holds 21,225 after (Direct).
  • Option exercise/conversion: disposed of 6,000 Performance Stock Units on August 14, 2026 (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $91,639 of stock on the open market.

Insider Transactions

Jonathan Allan — Officer (GENERAL COUNSEL & CORP SEC)

DateTransactionSecuritySharesPriceValueHeld After
2026-08-14Option exercise/conversionCommon Stock6,000——24,086
2026-08-18Open-market saleCommon Stock2,716$32$86.9K21,370
2026-08-18Open-market saleCommon Stock145$32$4.7K21,225
2026-08-14Option exercise/conversionPerformance Stock Units6,000——0

Key Dates

DateDescription
2026-08-14Option exercise/conversion (6,000 shares)
2026-08-18Open-market sale (2,716 shares)
2026-08-18Open-market sale (145 shares)
2026-08-14Option exercise/conversion (6,000 shares)

Keywords

insider transaction, Form 4, STOK, Stoke Therapeutics, Inc., bearish, Jonathan Allan

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.